Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.
This educational video is the first part of a serie called "Reviewing HFpEF: Lessons and implications from PARAGON-HF" that is aimed to give cardiologists and other health care professionals involved in the management of heart failure a well-balanced expert view on findings derived from the PARAGON-HF trial.
Milton Packer, MD, is an internationally recognized clinical investigator in the field of heart failure. He spent most of this career in New York City, where he was the Dickinson Richards Professor and Chief of the Division of CIrculatory Physiology at Columbia University. From 2004-2015 he was Professor and Chair of the Department of Clinical Sciences at the University of Texas Southwestern Medical Center at Dallas. Dr. Packer is currently the Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center, part of Baylor Scott & White Health.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from NovartisThe information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Reviewing HFpEF: Lessons and implications from PARAGON-HFHFpEF: A misunderstood disease in search of a therapy
Prof. Scott Solomon
- Reviewing HFpEF: Lessons and implications from PARAGON-HFHeart failure with mid-range ejection fraction
Prof. Burkert Pieske